<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00781781</url>
  </required_header>
  <id_info>
    <org_study_id>ALOTIRNE-EC06007</org_study_id>
    <secondary_id>2007-006440-22</secondary_id>
    <nct_id>NCT00781781</nct_id>
  </id_info>
  <brief_title>Alemtuzumab Use (MabCampath®) in Hematopoietic Transplant of Unrelated Donor With Reduced Intensity Conditioning</brief_title>
  <official_title>Multicenter, Openlabel, Phase II Intergroups (GELTAMO/GETH) Trial, on the Use of Alemtuzumab for Unrelated Donor Reduced Intensity Conditioning Allogenic Transplant in Hematological Malignancies Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CABYC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CABYC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to analyze the results of incidence and severity of acute and&#xD;
      chronic GVHD, (see addendum II) and of disease free survival with Alemtuzumab use&#xD;
      (MabCampath®) in haematopoietic transplant of unrelated donor with reduced intensity&#xD;
      conditioning.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each patient will be assigned to one of the two dosing schedules and total dose of drug&#xD;
      envisaged in the study. The assignation to conventional or reduced Alemtuzumab (MabCampath)&#xD;
      dose will be done depending on the age and risk of suffering GVHD, in function of variables&#xD;
      coming from general experience.&#xD;
&#xD;
      High risk of GVHD criteria:&#xD;
&#xD;
      Gender incompatibility: male patient of female donor. HLA incompatibility: non identical high&#xD;
      resolution typing in HLA A, B, C, DRB1, DQB1 (identity less than 10/10 alleles by high&#xD;
      resolution) Age of patient more or equal than 55 years&#xD;
&#xD;
      Conventional doses in high risk (at least one criterion of GVHD high risk):&#xD;
&#xD;
      100 mg de Alemtuzumab IV total dose in 5, 20 mg fractions, days -8, -7, -6, -5 and -4.&#xD;
&#xD;
      Reduced dose in low risk cases (no criteria of GVHD high risk):&#xD;
&#xD;
      50 mg de Alemtuzumab IV total dose en 5 fractions of 10 mg, days -5, -4, -3, -2 and -1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inability to recruit the number of patients established in the study protocol (34 of 40)&#xD;
  </why_stopped>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analyze the results of incidence and severity of acute and chronic GVHD</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Graft Versus Host Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High risk patients (at least one GVHD high risk criterion):&#xD;
Total dose 100 mg in 5 doses of 20 mg, days -8 to -4 (inclusive).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Risk patients (no GVHD high risk criterion):&#xD;
Total dose 50 mg inn 5 dosing OF 10 mg, days -5 to -1 (inclusive).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alemtuzumab</intervention_name>
    <description>High risk: Total dose 100 mg in 5 doses of 20 mg, days -8 to -4 (inclusive) Low risk: Total dose 50 mg inn 5 dosing OF 10 mg, days -5 to -1 (inclusive).</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>MabCampath</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Patients with haematological or lymphoid malignancies with allogenic transplantation&#xD;
             indication:&#xD;
&#xD;
               -  High risk follicular NHL, mantle HHC and other low grade NHC (e.g&#xD;
                  lymphoplasmacytic, extranodal or from marginal zone).&#xD;
&#xD;
                    1. Disease that does not obtain a CR with Fludarabine or antiCD-20 including&#xD;
                       chemotherapy.&#xD;
&#xD;
                    2. Relapse after autologous transplant.&#xD;
&#xD;
                    3. Non candidates to autologous transplant in 2nd CR (e.g. mobilization&#xD;
                       failure, or persistent marrow infiltrate).&#xD;
&#xD;
               -  Poor prognosis chronic lymphoblastic leukaemia (CLL): Del 11q, Del 17p, complex&#xD;
                  cariotype; B symptoms, progressive low cell count by marrow infiltration,&#xD;
                  lymphocytosis or enlarged lymph nodes, or progressive spleen growth.&#xD;
&#xD;
               -  High grade lymphoma transformed from a low grade non Hodgkin's lymphoma or from a&#xD;
                  chronic lymphocitic leukaemia&#xD;
&#xD;
               -  High risk T peripheral lymphoma, with IPI &gt; or = 2, non susceptible of autologous&#xD;
                  transplant, or relapsed after autologous transplant&#xD;
&#xD;
               -  Primarily refractory high risk Hodgkin's disease, relapse in patients not&#xD;
                  susceptible of autologous transplant or relapse after autologous transplant.&#xD;
&#xD;
               -  High risk acute mieloblastic leukaemia (AML) in 1st CR, or AMC &gt; or = 2 CR,&#xD;
                  including AML after MDS and secondary AML.&#xD;
&#xD;
               -  High risk acute lymphoblastic leukaemia (ALL) because of poor response to&#xD;
                  induction chemotherapy (&gt;10% blasts day +14 or no RC day +28-35), or by&#xD;
                  cytogenetic criteria: Ph+ or 11q23.&#xD;
&#xD;
               -  High risk myelodisplastic syndromes (SMD) type RAEB-1 or AREB-2 with IPSS &gt;Int-1.&#xD;
&#xD;
          -  For the inclusion in transplant patients with ALL or AML must be in CR, patients with&#xD;
             MDS must have &lt;10% blasts en la BM, and patients with lymphoid malignancies must show&#xD;
             previous chemosensitivity, with PR or CR.&#xD;
&#xD;
          -  Patients 40 to 65 years old. Patients outside this age range could be included&#xD;
             according to participating centres criteria.&#xD;
&#xD;
          -  Patients in the study population lacking a compatible related donor, and with a&#xD;
             possible compatible unrelated donor (&gt;=9/10 by 10 alleles high resolution typing:&#xD;
             HLA-A, B, C, DRB1, DQB1) to assign the patients to a risk in subgroup.&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
          -  Not fulfilling any of the following exclusion criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Liver (≥ x3 UNL), kidney (GF &lt;40ml/min), cardiac (LVEF &lt;40%) or respiratory (DLCO &amp;&#xD;
             FVC &lt;40% of expected) function tests impairment.&#xD;
&#xD;
          -  HIV injection.&#xD;
&#xD;
          -  Absence of signed informed consent.&#xD;
&#xD;
          -  Progressive disease previous to transplant or not fulfilling the above mentioned&#xD;
             response criteria.&#xD;
&#xD;
          -  Other co-morbidities that contraindicate CT.&#xD;
&#xD;
          -  Pregnant and/or breast-feeding women or with pregnancy risk by inadequate&#xD;
             contraception.&#xD;
&#xD;
          -  Life expectancy &lt;6 months.&#xD;
&#xD;
          -  Mental or psychiatric deficiency impeding adequate understanding and consent to&#xD;
             therapy&#xD;
&#xD;
          -  Hypersensitivity as shown by anaphylactic reaction to any of the DRUGS used in the&#xD;
             trial.&#xD;
&#xD;
          -  Active infectious process.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafael Duarte, MD, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>ICO Bellvitge. Hospital Duran i Reynals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial.</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico de Valencia</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vall de Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <study_first_submitted>October 28, 2008</study_first_submitted>
  <study_first_submitted_qc>October 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2008</study_first_posted>
  <last_update_submitted>February 3, 2015</last_update_submitted>
  <last_update_submitted_qc>February 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myeloid and Lymphoid malignances</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

